The dynamics of monocytes and microglia in Alzheimer’s disease by Peter Thériault et al.
Thériault et al. Alzheimer's Research & Therapy  (2015) 7:41 
DOI 10.1186/s13195-015-0125-2REVIEW Open AccessThe dynamics of monocytes and microglia in
Alzheimer’s disease
Peter Thériault, Ayman ElAli and Serge Rivest*Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting older people worldwide. It is a
progressive disorder mainly characterized by the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles
within the brain parenchyma. It is now well accepted that neuroinflammation constitutes an important feature in
AD, wherein the exact role of innate immunity remains unclear. Although innate immune cells are at the forefront
to protect the brain in the presence of toxic molecules including Aβ, this natural defense mechanism seems insufficient
in AD patients. Monocytes are a key component of the innate immune system and they play multiple roles, such as
the removal of debris and dead cells via phagocytosis. These cells respond quickly and mobilize toward the inflamed
site, where they proliferate and differentiate into macrophages in response to inflammatory signals. Many studies have
underlined the ability of circulating and infiltrating monocytes to clear vascular Aβ microaggregates and parenchymal
Aβ deposits respectively, which are very important features of AD. On the other hand, microglia are the resident
immune cells of the brain and they play multiple physiological roles, including maintenance of the brain’s
microenvironment homeostasis. In the injured brain, activated microglia migrate to the inflamed site, where
they remove neurotoxic elements by phagocytosis. However, aged resident microglia are less efficient than their
circulating sister immune cells in eliminating Aβ deposits from the brain parenchyma, thus underlining the
importance to further investigate the functions of these innate immune cells in AD. The present review summarizes
current knowledge on the role of monocytes and microglia in AD and how these cells can be mobilized to prevent
and treat the disease.Introduction
Alzheimer’s disease (AD) is the most prevalent cause of
dementia in older people worldwide. This disease is a
neurodegenerative disorder characterized by the progres-
sive loss of memory and cognitive functions. Amyloid-beta
(Aβ) deposition in brain parenchyma and blood vessels
constitutes a major pathological hallmark of AD [1].
Neurotoxic Aβ1–40 and Aβ1–42 peptides derived from the
sequential proteolytic cleavage of the amyloid precursor
protein (APP), mediated by the activity of β-secretases and
γ-secretases, accumulate and form soluble oligomers,
which over time aggregate to form extracellular insoluble
Aβ plaques [1].
Cerebral soluble Aβ accumulation has been proposed
to be associated with faulty clearance of this peptide from
the brain [2]. The early formation and accumulation of Aβ* Correspondence: serge.rivest@crchudequebec.ulaval.ca
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unless otherwise stated.oligomers in the cerebral vasculature causes the brain’s
microvascular dysfunction and contributes to the develop-
ment of cerebral amyloid angiopathy (CAA), which takes
place in 80% of AD cases [3]. Interestingly, microvascular
blood–brain barrier (BBB) dysfunction has been reported
in early stages of AD [4]. The BBB collaborates with the
periphery and brain parenchyma in order to eliminate Aβ
from the brain through several sophisticated mechanisms.
These mechanisms include Aβ oligomer degradation by
specialized enzymes [5], soluble Aβ transport by special-
ized transport systems [3,6], soluble Aβ elimination via
the cerebral interstitial fluid bulk flow [7], soluble Aβ
elimination by vascular patrolling monocytes [8] and
soluble and insoluble Aβ internalization and degradation
by microglia [9].
Although the link between parenchymal Aβ plaque de-
position and cognitive decline remains controversial, the
detrimental roles of soluble Aβ oligomers in the AD
brain have been demonstrated [1], such as inflammation.
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tion [10,11], microglia activation [12], reactive astrocytes
[13] and monocyte recruitment to brain vasculature, infil-
tration into brain parenchyma and their subsequent ac-
tivation [14]. Several studies have demonstrated a close
relationship between neuroinflammation and AD path-
ology [15]. Until recently, neuroinflammation in AD has
been exclusively linked to Aβ [16]. However, recent studies
have outlined a potential contribution of systemic and local
mild chronic inflammation in initiating the neurodegenera-
tive cascade observed in AD [17,18]. Although the link be-
tween neuroinflammation and AD pathology is now well
recognized, how brain innate immunity is driven in AD is
still a matter of debate – especially whether neuroinflam-
mation can be triggered by age-related systemic inflamma-
tion [19]. This phenomenon can directly mediate BBB
dysfunction in the early stages of AD, thus triggering mild
chronic cerebral inflammation that evolves over time [3].
In this review, we aim to highlight the dynamics of
monocytes and microglia in AD. More precisely, we will
review their interaction with the BBB and brain paren-
chyma and the implication of such an interaction on AD
pathogenesis. Finally, we will be outlining potential ap-
proaches that aim to target these cells, such as cell trans-
plantation and immunomodulation, in order to develop




Monocytes constitute a population of circulating leuko-
cytes that are central cells of the innate immune system.
They are part of the mononuclear phagocyte system that
arises from the hematopoietic system, which is constituted
by self-renewal hematopoietic stem cells and progenitor
cells located in the bone marrow (BM) [20]. Monocytes
come from the monocyte–macrophage dendritic cell pro-
genitor and are incompletely differentiated cells that give
rise to a heterogeneous mononuclear phagocyte lineage
[20]. They express multiple clusters of differentiation
(CD), namely CD115, CD11c, CD14 and CD16 in human
or CD115, CD11b and Ly6C in mouse [21]. In parallel,
both human and murine monocytes express different levels
of chemokine receptors, among which are chemokine
(C-X3-C motif ) receptor 1 (CX3CR1) and chemokine
(C-C motif ) receptor 2 (CCR2) [22]. In human, mono-
cytes are regrouped into three main subsets based on their
CD14 and CD16 expression levels, which are the clas-
sical subset (CD14++CD16−), the intermediate subset
(CD14++CD16+) and the nonclassical subset (CD14+
CD16++) [23]. In mouse, monocytes are regrouped into
two main subsets based on chemokine receptors and
Ly6C expression levels; namely the proinflammatory sub-
set (CX3CR1lowCCR2+Ly6Chigh) that is actively recruitedto inflamed tissues and contributes to inflammatory re-
sponses, and the anti-inflammatory subset (CX3CR1high
CCR2−Ly6Clow) that constitutes the resident patrolling
monocyte population which patrols the lumen of blood
vessels and promotes tissue repair [22].
Monocytes are very potent phagocytic cells that respond
to stress signals by expressing a variety of surface mole-
cules, among which are scavenger receptors (for example,
scavenger receptor SR-A, CD36), low-density lipoprotein
receptors (for example, low-density lipoprotein receptor-
related protein, LRP1), toll-like receptors (for example,
TLR2, TLR4), chemokine receptors (for example, CCR2,
CX3CR1), cytokine receptors (for example, macrophage
colony-stimulating factor (M-CSF) receptor), Fcγ receptors
and adhesion molecules (for example, leukocyte function-
associated antigen, LFA-1), wherein the expression level
of these molecules reflects their respective functions [21].
Monocytes are involved in innate immunity by defend-
ing the organism against pathogens and toxins [21]. Little
is known about monocyte interaction with the brain under
physiological conditions. However, it has been proposed
that circulating monocytes – more precisely, the patrolling
subset that has a long half-life [22] – replenish the peri-
vascular macrophage population in normal tissue, which
is involved in maintenance of homeostasis of the peri-
vascular space (Figure 1) [24]. Under pathophysiological
conditions, short-lived circulating proinflammatory mono-
cytes are mobilized from the BM to the blood circulation
in a CCR2-dependent manner [25,26]. These cells have
been shown to possess the capacity to infiltrate inflamed
tissues of several organs, including the brain [23]. The in-
filtration rate of monocytes increases in response to brain-
derived inflammatory cues [27]. Following injured brain
infiltration, monocytes can differentiate into activated
macrophages that are involved in the production of
various inflammatory molecules, such as interleukin-1β
and tumor necrosis factor α [21], and phagocytosis of
toxic elements, including Aβ [27]. It is noteworthy to
mention that morphologically these monocyte-derived
macrophages are indistinguishable from brain resident
microglial cells, but functionally they show a more effica-
cious phagocytic capacity (Figure 2) [27]. As discussed,
the infiltration of monocyte subsets in the inflamed
brain and their differentiation into macrophages totally
depend on the inflammatory cues present within their
microenvironment.
Monocyte dynamics in Alzheimer’s disease
Monocyte interactions with the blood–brain barrier
Although both monocyte subsets interact with the brain
in AD, the anti-inflammatory monocyte subset seems to
have a more functionally intimate relationship with the
BBB compared with the proinflammatory subset. On the
other hand, the interaction of the proinflammatory
Figure 1 Innate immunity profile in the healthy brain. Intact blood–brain barrier (BBB) formed by tightly sealed endothelial cells (EC) and the
basal lamina containing extracellular matrix components (for example, collagen, fibronectin). The BBB restricts entry into the brain of pathogens,
toxins and blood-borne molecules, such as immunoglobulin, albumin, thrombin, plasmin, fibrin and laminin. Bone marrow-derived circulating
monocytes are divided in two main subsets, which are the patrolling anti-inflammatory (Ly6Clow) monocytes and the circulating proinflammatory
(Ly6Chigh) monocytes. Ly6Clow monocytes are long-lived cells that ensure continuous surveillance by crawling on blood vessel lumen. Ly6Chigh
monocytes are short-lived cells that are present in blood circulation. Perivascular macrophages (PM) probably arise from Ly6Clow monocytes and
contribute to the maintenance of homeostasis of the perivascular space, mainly via its phagocytic activity. Quiescent microglia (QM) maintain a
healthy brain microenvironment suitable for neurons (N), by continuously sensing any occurring changes via their high ramifications, secreting
neurotrophic factors, namely brain-derived neurotrophic factor, and promoting neuronal remodeling and synaptic plasticity.
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of transmigration, which is an obligatory process to
reach brain parenchyma. For instance, it has been shown
that anti-inflammatory monocytes behave as house-
keepers within the vasculature by surveying the endothe-
lium [28,29]. Several reports outlined the importance of
these anti-inflammatory monocytes in AD. More pre-
cisely, it has recently been shown that the nonclassical
CD14+CD16++ monocytes in human, which are compar-
able with mouse anti-inflammatory CX3CR1highCCR2−
Ly6Clow monocytes, are reduced in AD patients compared
with mild cognitive impairment patients or age-matched
healthy controls [30]. In addition, our group demonstrated
using the two-photon intravital imaging approach that the
patrolling monocyte subset adhered in a specific manner to
Aβ-rich brain vasculature, and efficaciously eliminated Aβ
microaggregates by internalizing and transporting them
from the brain microvasculature to the blood circulation(Figure 2) [8]. BM-derived progenitor cells isolated from
Nr4a1−/− mice, which is a transcription factor implicated in
the differentiation of anti-inflammatory Ly6Clow monocytes
within the BM and their survival [31], were transplanted
in APP/PS1 mice to address their role in this observa-
tion [8]. Importantly, this specific depletion of the anti-
inflammatory monocyte subset in APP/PS1 mice increased
Aβ deposition within the brain vasculature, which was
sufficient to increase overall brain Aβ levels, thus wors-
ening the cognitive function of these mice [8]. Taken
together, these observations outline the crucial role of
the interaction of these cells with the brain vasculature
in AD.
Monocyte interactions with the brain parenchyma
Circulating monocytes are able to infiltrate the brain in
AD [27]. BM-derived macrophages, which originate essen-
tially from infiltrated proinflammatory monocytes, have
Figure 2 Innate immune responses in the Alzheimer’s disease brain. Age-induced cerebrovascular dysfunction induces deregulation of tight
junction protein expression, which compromises the integrity of the blood–brain barrier (BBB). A compromised BBB promotes the entry of blood-
borne molecules within the perivascular space and brain parenchyma. Patrolling (Ly6Clow) monocytes are mobilized by inflammatory cues triggered by
vascular amyloid-beta (Aβ) microaggregates, contributing to their phagocytosis. Circulating proinflammatory (Ly6Chigh) monocytes are also mobilized
by brain-derived inflammatory cues, adhere to brain endothelium and consequently infiltrate brain parenchyma. Aβ-induced inflammatory conditions
promote the differentiation of Ly6Chigh monocytes into bone marrow-derived macrophages (BMDM) that exhibit enhanced Aβ phagocytic activity.
Perivascular macrophages (PM) could contribute to parenchymal Aβ deposit elimination via an efficient Aβ species clearance at the BBB. In an
Aβ-induced inflammatory microenvironment, neurons (N) become stressed leading to their dysfunction and ultimately their death. Taken together, the
presence of Aβ plaques, soluble Aβ species, proinflammatory molecules and blood-borne molecules constitute a stressful microenvironment that
activates the quiescent microglia (QM). Amoeboid activated microglial cells can adopt two main phenotypes that coexist in Alzheimer's disease brain:
M1 classically activated microglia (AM1) and M2 alternatively activated microglia (AM2). The switch between these two extreme phenotypes is
influenced by age and disease progression. The AM1 phenotype is involved in Aβ phagocytosis and proinflammatory actions, such as secretion of
cytokines/chemokines within the brain parenchyma. The AM2 phenotype is also involved in Aβ phagocytosis, but in contrast they have anti-inflammatory
actions, including damaged tissue repair and remodeling, and cytokine/chemokine production. EC, endothelial cells.
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in clearing cerebral Aβ deposits in AD models [9]. Mono-
cyte chemoattractant protein (MCP)-1 (or chemokine
(C-C motif) ligand 2 (CCL2)), which is produced by Aβ-induced activated microglial cells, triggers the mobilization
of proinflammatory monocytes in the inflamed brain
through CCR2 (that is, MCP-1 receptor) (Figure 2) [23].
This MCP-1/CCR2 axis seems to be crucial for monocyte
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mice, as the depletion of CCR2 reduced the infiltration of
these cells in the inflamed brain parenchyma, and conse-
quently reduced the presence of BM-derived macrophages
in the vicinity of Aβ plaques, thus increasing cerebral Aβ
deposition [32,33]. This observation highlights the role
of the MCP-1/CCR2 axis in the recruitment of proin-
flammatory monocytes into the inflamed brain and their
subsequent contribution to parenchymal Aβ clearance.
However, it was recently demonstrated that interleukin-1β
overexpression in the hippocampus of CCR2-deficient
APP/PS1 mice significantly reduced the amyloid plaques
loading in the inflamed hippocampus [34]. Interestingly,
immune cells were still observed in the hippocampus of
these mice, thus suggesting that CCR2+ monocytes are
not involved in interleukin-1β-mediated Aβ deposit clear-
ance [34]. This observation is highly important because it
suggests the implication of other immune cell types that
are recruited into the inflamed brain independently of the
MCP-1/CCR2 axis. Although infiltrated monocytes are
considered more efficacious than resident microglia in
Aβ clearance, impaired phagocytic capacity of circulat-
ing monocytes has been reported in AD. For instance,
Aβ phagocytosis by monocytes isolated from the blood
of AD patients showed poor differentiation into macro-
phages, reduced Aβ internalization and increased apop-
tosis, comparative with age-matched controls [35]. Recently,
an expression quantitative trait locus study performed in
purified AD patients’ leukocytes has identified monocyte-
specific susceptibility alleles, namely CD33 [36], that
are associated with diminished Aβ internalization [37].
In the perivascular space, a distinct population of macro-
phages exists that is characterized by the expression of
acid phosphatase, the activity of nonspecific esterase, the
expression of the scavenger receptor CD163 and the ex-
pression of mannose receptor CD206 [38]. In contrast to
normal resident microglia, perivascular macrophages are
regularly replenished by the differentiation of infiltrating
monocytes (Figure 1) [39]. Although little is known about
perivascular macrophages, they have been demonstrated
to act as antigen-presenting cells, to possess a phagocytic
activity and to actively respond to brain inflammation
[38]. Importantly, the specific depletion of these cells in
transgenic AD mouse models highly increased Aβ depos-
ition in the brain microvasculature and consequently in
the brain parenchyma [38]. This important observation
suggests that these cells could somehow assist the BBB in
Aβ clearance. Interestingly, it is proposed that an excessive
transport of Aβ species from parenchymal Aβ plaques to-
wards blood circulation contributes to CAA development
[40]. In parallel, it has been reported that parenchymal Aβ
deposit targeting by immunotherapy approaches could trig-
ger vascular Aβ deposition, thus leading to CAA develop-
ment [40,41]. Therefore, it would be of great interest to lookmore closely into the implication of such approaches
on the activity of perivascular macrophages, which would
outline the lacking link between an efficient parenchymal
Aβ elimination and efficient Aβ clearance across the BBB.
Microglia
Origin and function
Microglia are the resident macrophages of the brain, and
constitute the main active immune cells in the brain.
Although the origin of microglia is still elusive, it is well
accepted that these cells arise from myeloid precursors
and constitute an ontogenically distinct population of
mononuclear phagocytes [42]. As such, microglial cells
arise from hematopoietic progenitors in the yolk sac
during embryogenesis and are generated in the postna-
tal stage just after the formation of the BBB [39]. In the
adult brain, local self-renewal is sufficient for the main-
tenance of the microglial population pool [39]. Microglia
are therefore physiologically dependent on the colony-
stimulating factor 1 receptor signaling that is a key regula-
tor of myeloid lineage cells [42], because its ablation in
adult mice results in depletion of 99% of the microglial
cell population [43].
Microglia survey the brain and are actively involved
in maintaining the brain’s microenvironment by rapidly
responding to pathogens and/or damage (Figure 1) [24,44].
Moreover, microglial cells adopt a special phenotype and
cellular morphology that is characterized by high rami-
fications that constitute dynamic and motile sentinels,
by which microglia sense any occurring change in their
close microenvironment [24,45]. Under physiological con-
ditions, recent reports show that microglia actively contrib-
ute to neuronal plasticity and circuit function [46]. More
precisely, microglial cells are suggested to be involved
in controlling neuronal circuits’ maturation and shaping
neuronal connectivity [47]. The chemokine (C-X3-C motif)
ligand 1 (CX3CL1; also called fractalkine) signaling pathway
plays a key role in this physiological interaction between
microglia and neurons [47]. CX3CL1 is secreted by neurons
and binds to its receptor, CX3CR1, which is exclusively
expressed on microglial cells in the healthy brain [46]. The
CX3CL1/CX3CR1 axis plays a crucial role in regulating
microglial dynamic surveillance and migration throughout
the brain parenchyma, thus ensuring the survival of de-
veloping neurons and the maintenance of developing
and matures synapses. This axis is therefore directly in-
volved in brain functional connectivity, adult hippocampal
neurogenesis and the behavioral outcome [46].
Under pathophysiological conditions, microglial cells are
activated and acquire a new morphology characterized by
an amoeboid shape. Activated microglial cells are capable
of performing several macrophage-like immune functions,
such as cytokine release and phagocytosis (Figure 2)
[44,45]. In parallel with the newly acquired morphological
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markers involved in phagocytosis, namely macrophage
antigen complex (Mac)-1 and SR-A [45]. Once activated,
microglia can adopt diverse phenotypes ranging between
two extremes: a classically activated M1 phenotype
that is involved in proinflammatory actions, and an al-
ternatively activated M2 phenotype that is mainly in-
volved in anti-inflammatory actions and tissue repair
(Figure 2) [39]. The molecular cues present within the
microglial microenvironment play a crucial role in me-
diating their activation phenotype. It is important to
mention that, in the diseased brain tissue, both extremes
cohabit within a spectrum of different intermediate
phenotypes.
Microglia dynamics in Alzheimer’s disease
Microglial cell interactions with the blood–brain
barrier The neurovascular unit, which is constituted by
endothelial cells, extracellular matrix, pericytes, astro-
cytes, microglia and neurons, regulates the brain micro-
environment by controlling cerebral microcirculation
and adjusting the BBB’s parameters based on brain needs
[3]. Being a main constituent of the neurovascular unit,
microglia are actively involved in maintaining a healthy
brain microenvironment that is crucial for neuronal
function and survival [48]. In parallel, the activation of
microglia is narrowly dependent on their local microenvir-
onment. As mentioned, BBB abnormalities and alterations
have been reported in the early stages of AD development
[49]. More precisely, it has been suggested that, at the very
early stages of the disease, the brain microcirculation is
impaired and leads to microvascular dysfunction, thus
leading to cerebral chronic hypoperfusion [4]. These early
events impair BBB function, leading to a faulty clearance
of Aβ oligomers and its accumulation within the brain,
which induces neuronal stress [2]. At this stage of the
disease, microglial cells through their processes begin
to sense neuronal stress [24,44].
Over time, Aβ accumulation within the perivascular
space worsens BBB dysfunction caused by a significant de-
crease in the expression of tight junction proteins between
brain endothelial cells, thus increasing BBB permeability
to blood-borne molecules such as immunoglobulins, albu-
min, thrombin, plasmin, fibrin and laminin (Figure 2) [3].
The accumulation of these molecules within the perivas-
cular space exacerbates the microvascular damage and
triggers BBB total breakdown [3]. Over time, these mole-
cules trigger microglial cell overactivation (Figure 2). In
AD/CAA patients, activated microglial cells that are asso-
ciated with the BBB express increased protein levels of
C3b and Mac-1 [50]. Moreover, it has been shown that
the interaction between C3b and CD11b with Aβ is in-
creased in AD/CAA patients [50]. It was suggested that
these BBB-associated microglia, via their CD11b receptor,deliver Aβ/C3b complex to brain endothelial cells, thus
possibly enhancing Aβ elimination across the BBB [50].
This observation is highly important because it outlines
interesting mechanisms, via which the BBB and microglia
functionally interact to eliminate brain-derived toxic
molecules, such as Aβ, which should be further dissected.
Besides, microglial cells have been shown to express high
levels of the ATP-binding cassette transporter subfamily A
member (ABCA1; that is, cholesterol efflux regulatory
protein), which is an efflux pump for cholesterol and
phospholipids that contribute to apolipoprotein E lipi-
dation in the brain [51]. The rate of apolipoprotein E
lipidation is tightly involved in mediating Aβ uptake by
the former, thus contributing to Aβ clearance through
the BBB via endothelial LRP1 [52,53]. In parallel, a recent
study in APP/PS1 mice showed that the administration of
bexarotene, which is a retinoid X receptor agonist, specif-
ically induced apolipoprotein E expression by microglia,
which resulted in enhanced clearance of soluble Aβ
[54]. Taken together, these observations suggest a highly
dynamic and functional interaction at the neurovascular
unit, between microglia and the BBB, which has deep
implications in Aβ clearance.
Microglial activity within the brain parenchyma In
AD, microglia constitute the first responders to cerebral
Aβ accumulation, as they have been shown to be highly
associated with Aβ plaques and involved in Aβ phago-
cytosis [9,55]. Microglial cells are directly activated by
most Aβ species via several mechanisms that include
pattern recognition receptors such as TLRs, and other
receptors including receptor for advanced end glycation
products (RAGE), LRP1, scavenger receptors and com-
plement receptors [44,48]. Several hypotheses have been
formed to explain this distinctive feature of microglia
surrounding Aβ plaques. The first initial hypothesis sug-
gested that microglia are exclusively proinflammatory in
AD and have a detrimental role in the disease’s develop-
ment [27,56]. As such, some studies reported the regres-
sion of AD pathogenic features following nonsteroidal
anti-inflammatory drug treatment [56]. However, clinical
trials using nonsteroidal anti-inflammatory drugs to treat
AD were inconclusive [56].
The role of microglia in the AD brain was therefore
revised, and several recent and emerging data are suggest-
ing a more complex role of microglial cells in AD [15]. As
a crucial component associated with microglia’s physio-
logical role, the contribution of the CX3CL1/CX3CR1 axis
in AD pathogenesis has been actively investigated. For in-
stance, it has been shown that the ablation of CX3CR1 in
AD mouse models, namely APP/PS1 and R1.40, attenu-
ates Aβ deposition by modulating the phagocytic activity
of microglial cells [57]. By contrast, a study performed in
the 5 × Tg-AD mouse model revealed that CX3CR1-
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neuronal loss [58]. These observations therefore highlight
important concerns about experimental parameters, such
as transgenic animal models and neuroinflammatory con-
ditions, which impact differently on the CX3CR1 signaling
involved in neuron–microglia communication. In parallel,
the efficacy of resident microglia that surround Aβ pla-
ques in degrading Aβ species is still elusive. As such,
microglia that are spatially associated with Aβ plaques
have been shown to contain Aβ species in their endo-
plasmic reticulum, a nonphagocytic specialized organelle,
suggesting that resident microglia do not actively partici-
pate in Aβ phagocytosis [59]. By contrast, it has been
shown that microglia are indeed capable of internalizing
fibrillar and soluble Aβ, but are unable to process these
peptides [60]. Importantly, in AD patients that underwent
a cerebral ischemic attack, which highly compromised the
BBB, circulating monocytes massively infiltrate the brain
parenchyma where they differentiate into macrophages
[61]. These infiltrated macrophages contained Aβ species
within their lysosomes, a specialized phagocytic organelle,
pointing toward an efficacious phagocytosis [61]. More-
over, it has been shown that APP/PS1 mice irradiation
and subsequent transplantation of BM-derived progenitor
cells gave rise to monocyte-derived microglial cells, which
originate from infiltrating monocytes capable of migrating
throughout brain parenchyma, specifically surround Aβ
plaques and efficaciously eliminate the latter (Figure 2)
[9]. Taken together, these observations suggest a crucial
impact of brain parenchyma microenvironment on cells’
phagocytic capacity. For instance, newly infiltrated macro-
phages, which were less exposed to Aβ aggregates and
proinflammatory cues, appear more efficient than brain
resident microglia, which were highly exposed to Aβ
aggregates and proinflammatory cues.
AD is an age-related progressive neurodegenerative dis-
ease with different development stages, which could ex-
plain the multifaceted roles of microglia in AD. Microglial
cells undergo significant changes in their phenotype,
and their activity is impaired with age. In aged brain,
microglial cells exhibit an altered shape and dystrophic
processes, and seem to be hyper-responsive to mild in-
flammatory stimulations [62]. Importantly, most proin-
flammatory cytokines that are produced by aged microglia
are controlled by the CX3CL1/CX3CR1 signaling pathway
[63], which translates a progressive dysfunctional inter-
action between microglia and neurons with age. In AD,
the early activation of microglial cells has been proposed
to be beneficial by promoting clearance of Aβ before
plaque formation [64]. However, over time microglial
cells lose their protective role, due to the persistent pro-
duction and accumulation of proinflammatory cytokines
within their microenvironment [65]. Under such condi-
tions, microglial cells become hypersensitive and play adetrimental role through the excessive continuous pro-
duction and secretion of proinflammatory and neurotoxic
molecules [65]. In parallel, the expression levels of several
microglial markers involved in Aβ uptake and phagocyt-
osis have been shown to be impaired [65]. Interestingly,
RNA sequencing in aged microglia has identified numer-
ous age-related microglial changes, such as a downreg-
ulation of transcripts encoding for endogenous ligand
recognition proteins, an upregulation of those involved
in host defense and pathogen recognition, in addition
to an increased expression of neuroprotective genes [66].
This observation is interesting because it suggests that
microglia can adopt a neuroprotective phenotype with
age. Therefore, it is important to take these factors into
consideration when drawing a complete picture of the
role of microglia in AD pathogenesis.
Targeting monocytes and microglia as a novel therapeutic
approach in Alzheimer’s disease
Monocytes and microglia constitute two major players
involved in AD etiology. Lessons obtained from many
recent studies highlighted these cells as potential targets
for AD treatment.
Cell therapy
Several studies have shown that progenitor cell trans-
plantation decelerates the pathogenic features of AD by
affecting mainly brain innate immune function. An ele-
gant study reported that the systemic administration of
human umbilical cord blood cells reduced the levels of
parenchymal and vascular Aβ by specifically increasing
the phagocytic capacity of microglial cells and by inhibit-
ing interferon γ mediated microglial activation [67]. Inter-
estingly, it has been suggested that the monocytes
derived from healthy individuals phagocyte Aβ more ef-
ficiently than monocytes derived from AD individuals
[68]. In parallel, as mentioned, our group has shown that
microglial cells which originate from BM-derived pro-
genitor cells are more efficacious in Aβ phagocytosis and
clearance compared with resident microglia [9]. Taken
together, these observations are extremely important be-
cause they outline the transplantation of BM-derived pro-
genitor cells from healthy individuals into AD individuals
as a potential therapeutic approach. Indeed, it has been
shown that the intracerebral transplantation of BM-
derived mesenchymal stem cells reduced Aβ deposition
and enhanced the cognitive functions of an AD mouse
model, mainly by modulating brain immune responses
[69]. Recently, the transplantation of adipose-derived
mesenchymal stem cells, which are considered as a new
cell source for regenerative therapy, has been shown to
be a promising avenue in treating AD [70]. The trans-
plantation of these cells decelerates the pathogenic fea-
tures of AD in a mouse model of AD by alternatively
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cells’ reduced production of proinflammatory mediators
and accompanied by an increased expression of microglial-
derived enzymes involved in Aβ degradation [70].
Interestingly, the beneficial effects of stem/progenitor
cell transplantation seem to go beyond the cell’s capacity
to directly differentiate into microglial cells. More precisely,
stem/progenitor cell transplantation has been proposed to
also modulate the microenvironment of resident microglial
cells and to enhance the metabolic activity in the vicinity
of microglia. For example, an in vitro study showed that
the co-culture of the immortalized murine microglial
cell line BV2 with human umbilical cord blood-derived
mesenchymal stem cells increased the microglial cell
expression of neprilysin, an enzyme involved in Aβ deg-
radation [71]. The transplantation of these cells in an
AD mouse model reduced Aβ deposition, which was
neprilysin dependent [71].
Cell stimulation and immunomodulation
As mentioned, resident microglial cells surrounding Aβ
plaques are not efficacious in degrading Aβ. Nonetheless,
it has been shown that their stimulation could enhance
their intrinsic phagocytic capacity to degrade Aβ more ef-
ficaciously. Moreover, it has been proposed that a shift
from a classical activation M1 phenotype that exacerbates
the inflammatory response towards an alternative activa-
tion M2 phenotype that promotes tissue repair would
enhance cerebral Aβ clearance [11].
As such, an early study showed beneficial effects of an
intra-hippocampal injection of lipopolysaccharide, which
is a TLR4 ligand, in a mouse model of AD [72]. The authors
observed an increased activation of resident microglial cells,
which was accompanied by a significant reduction of cere-
bral Aβ load within the brain parenchyma of mice fol-
lowing lipopolysaccharide administration [72]. These
results outline that the early activation of microglia pro-
motes Aβ phagocytosis, while later activation could con-
tribute to chronic inflammation and neurodegeneration.
In parallel, our group recently demonstrated that the
chronic systemic administration of a detoxified TLR4
ligand, which is a lipopolysaccharide derivative called
monophosphoryl lipid A, potently decelerated AD-related
pathology in a mouse model of AD, by significantly redu-
cing cerebral Aβ deposits and ameliorating the cognitive
functions of these mice [73]. Monophosphoryl lipid A
early treatment enhanced Aβ phagocytosis by mono-
cytes and microglia without inducing a potentially
harmful inflammatory response, such as observed with
lipopolysaccharide.
Other similar strategies using molecules that modulate
monocyte and microglial activity have also showed inter-
esting results. M-CSF is a hematopoietic growth factor
involved in the proliferation, differentiation and survivalof monocytes, macrophages and BM-derived progenitor
cells [74]. M-CSF receptor overexpression in an AD mouse
model resulted in an increased antibody-opsonized Aβ
phagocytosis by microglial cells [75]. In parallel, M-CSF
treatment of a mouse model of AD improved their cog-
nitive function, which was accompanied by reduced Aβ
deposits in brain parenchyma [76]. Importantly, M-CSF
treatment increased the number of microglial cells sur-
rounding plaques, which was accompanied by a higher
rate of Aβ internalization by these cells [76]. Taken to-
gether, these observations showed that the early activation
of monocytes and microglia constitutes an interesting
strategy to, at least, decelerate AD progression. Moreover,
these studies underlie the beneficial roles of such mole-
cules as modulator of immune responses, which potenti-
ate the intrinsic phagocytic capacity of monocytes and
microglia without triggering an exacerbated inflammation
that could worsen AD pathology.
Finally, the lipid mediator palmitoylethanolamide, which
is an endogenous fatty acid amide present in microglial
cells, has been reported to modulate the microglial cell
phenotype [77]. Indeed, palmitoylethanolamide has been
suggested to be involved in controlling microglial cell
alternative activation by enhancing their migration cap-
acity, via its interaction with a cannabinoid-like receptor
[77]. Interestingly, a recent study reported an unknown
therapeutic potential of palmitoylethanolamide in AD.
More precisely, in wildtype mice that were intracerebrally
injected with Aβ peptides, the administration of palmi-
toylethanolamide dose-dependently reduced Aβ-induced
memory impairments in a peroxisome proliferator-activated
receptor alpha-dependent manner [78].
Conclusions
In this review, we have attempted to underline the role
of monocytes and microglia in AD. Moreover, we out-
lined their relevance for the development of novel thera-
peutic strategies. The role of neuroinflammation in AD
is still a matter of debate. Many studies have shown con-
flicting results about the beneficial and deleterious effects
of neuroinflammation [15]. However, it is now well ac-
cepted that there is no ultimately good or bad neuroin-
flammation; it is context dependent. On one hand,
neuroinflammation mediates neuroprotective effects by
forming the first line of defense in the brain; on the
other, it mediates neurotoxic effects by exacerbating the
inflammatory response. Monocytes and microglia are
key innate immune cells implicated in AD etiology.
However, it is now urgent to further investigate the
multifaceted roles of these cells in AD by outlining the
complex regulatory molecular mechanisms that govern
the balance between their beneficial and detrimental ef-
fects in a context-dependent manner, especially during
the different stages of the disease’s development and
Thériault et al. Alzheimer's Research & Therapy  (2015) 7:41 Page 9 of 10age. Such an approach would allow the development of
novel therapeutic strategies that mainly focus on enhancing
Aβ elimination, without generating undesirable effects,
such as an exacerbated inflammation and neurotoxicity.Note: This article is part of a series on Innate Immunity,
edited by Donna Wilcock. Other articles in this series can be
found at http://alres.com/series/innateimmunityAbbreviations
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